Physiomics PLC Contract Award (3763E)
09 February 2018 - 6:00PM
UK Regulatory
TIDMPYC
RNS Number : 3763E
Physiomics PLC
09 February 2018
Physiomics plc
("Physiomics") or ("the Company")
Contract award
Physiomics secures third major pharmaceutical client in matter
of months
Physiomics plc (AIM: PYC), a provider of technology-based
solutions to predict the effects of cancer treatment regimens for
the biopharma industry, is delighted to announce that it has been
awarded a contract by a further major (global top-10)
pharmaceutical client. The project, which has a value of
approximately GBP70k, is expected to be completed during the
Company's current financial year and involves the use of
Physiomics' Virtual Tumour technology in a pre-clinical
setting.
Physiomics' Virtual Tumour is a sophisticated computer model
that simulates tumour cell division and predicts the effect of
different anti-cancer regimes to support pre-clinical and clinical
oncology development programs. Virtual Tumour helps customers to
balance efficacy and toxicity and to prioritise the most effective
drug combinations while reducing time and cost.
Dr Jim Millen, CEO said: "We believe that the signing of
agreements with three major pharmaceutical clients within the space
of three months is a real sign of the confidence in our technology
that is starting to build within the industry. Our aim now will be
to develop longer-term relationships with these major companies and
to secure further pre-clinical and clinical projects."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (nomad)
Katy Mitchell
James Sinclair-Ford
+44 (0) 161 832 2174
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is a solutions provider to the R&D
based pharmaceutical and biotechnology industry with a focus on
oncology. The Company's Virtual Tumour technology uses computer
modelling to predict the effects of cancer drugs and treatments to
improve the success rate of drug discovery and development projects
while reducing time and cost. The predictive capability of Virtual
Tumour has been confirmed by 55 projects, involving over 25 targets
and 60 drugs, and has worked with clients such as Merck KGaA, Merck
& Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 90 years collectively of working in
oncology and/or computational biology and over 100 publications in
peer reviewed journals.
For more information please visit:
www.physiomics-plc.com
www.twitter.com/Physiomics
www.linkedin.com/company/physiomics-plc/
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTUGUWUPUPRGMR
(END) Dow Jones Newswires
February 09, 2018 02:00 ET (07:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024